IDX logo

Integral Diagnostics Limited Stock Price

ASX:IDX Community·AU$745.0m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 18 Fair Values set on narratives written by author

IDX Share Price Performance

AU$0
-2.53 (-100.00%)
AU$3.11
Fair Value
AU$0
-2.53 (-100.00%)
Price AU$0

IDX Community Narratives

·
Fair Value AU$3.11 35.5% undervalued intrinsic discount

MRI Licensing And Lung Screening Will Expand Imaging Potential

0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
·
Fair Value AU$2.22 9.5% undervalued intrinsic discount

MRI Deregulation And Teleradiology Expansion Will Shape Modest Future Earnings Improvements

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value AU$4 49.8% undervalued intrinsic discount

AI And Teleradiology Expansion Will Drive Long Term Diagnostic Imaging Leadership

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AU$3.11
35.5% undervalued intrinsic discount
Revenue
7.11% p.a.
Profit Margin
7.28%
Future PE
20.89x
Price in 2029
AU$3.85
AU$4
49.8% undervalued intrinsic discount
Revenue
15.64% p.a.
Profit Margin
8.9%
Future PE
21.06x
Price in 2028
AU$4.86

Trending Discussion

Updated Narratives

IDX logo

IDX: Trimmed Outlook And Neutral Rating Will Define Near-Term Share Performance

Fair Value: AU$2.22 9.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
IDX logo

IDX: New Leadership And New Clinics Will Support Future Upside

Fair Value: AU$3.11 35.5% undervalued intrinsic discount
12 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
IDX logo

AI And Teleradiology Expansion Will Drive Long Term Diagnostic Imaging Leadership

Fair Value: AU$4 49.8% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Reasonable growth potential and fair value.

3 Risks
4 Rewards

Integral Diagnostics Limited Key Details

AU$767.8m

Revenue

AU$526.0m

Cost of Revenue

AU$241.8m

Gross Profit

AU$227.8m

Other Expenses

AU$14.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 25, 2026
0.038
31.50%
1.83%
50.1%
View Full Analysis

About IDX

Founded
1967
Employees
3000
CEO
Ian Kadish
WebsiteView website
www.integraldiagnostics.com.au

Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. The company offers magnetic resonance imaging, positron emission tomography, computed tomography mammography, interventional radiology, ultrasound, and radiography, such as x-ray and EOS. Integral Diagnostics Limited was founded in 1967 and is headquartered in Melbourne, Australia.

Recent IDX News & Updates

Narrative Update Jun 26

IDX: Trimmed Outlook And Neutral Rating Will Define Near-Term Share Performance

Analysts have trimmed their price target for Integral Diagnostics to A$2.15 from A$2.49, as updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E point to a more balanced risk and reward profile following recent share price performance. What’s in the News for Integral Diagnostics No recent news stories are available for Integral Diagnostics based on the provided sources.
Narrative Update May 11

IDX: New Leadership And New Clinics Will Support Future Upside

Analysts have trimmed their price target for Integral Diagnostics to A$3.11 from A$3.12 as they factor in a slightly higher discount rate and marginally softer profit margin expectations, while keeping revenue growth assumptions and future P/E largely unchanged. What's in the News New Managing Director and CEO Jason Martinez is scheduled to commence on 6 August 2026, with current Managing Director and CEO Dr Ian Kadish staying on until then to support a smooth leadership transition (Key Developments).

Recent updates

No updates